MedPage Today October 20, 2024
— However, questions remain about durability of vaccine protection, expert says
The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) visits in older patients during the first season of the vaccine’s rollout, according to a retrospective analysis.
From November 2023-April 2024, adjusted RSV vaccine effectiveness against hospitalizations or ED visits was 90% (95% CI 24-99) among adults ages 60 and older during the first 5 months of vaccine availability, reported Sara Tartof, PhD, MPH, of Kaiser Permanente in Pasadena, California, at the IDWeek annual meeting in Los Angeles.
Also, in a secondary analysis, adjusted vaccine effectiveness against RSV-related acute respiratory illness (ARI) ED visits was 93% (95% CI 47-99) and 91% against RSV-related...
Today's Sponsors
Today's Sponsor